The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of tissue-resident adaptive NK cells and their association with reduced mortality across diverse solid tumors.
 
John Lozada
No Relationships to Disclose
 
Atef Ali
No Relationships to Disclose
 
Christine Luo
No Relationships to Disclose
 
Rosemary Plagens
Employment - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Ella Boytim
Consulting or Advisory Role - Astrin Biosciences; Tempus
 
Nicholas Zorko
Consulting or Advisory Role - Bayer; Dendreon; Takeda (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Telix Pharmaceuticals
 
Wafik El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Research Funding - Chimerix
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences
 
Elisabeth Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Gilead Sciences; Novartis; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo Inc. (Inst); Eisai (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Sanofi
Other Relationship - Caris Centers of Excellence
 
Akash Patnaik
Stock and Other Ownership Interests - Gilead Sciences; Infinity Pharmaceuticals; Merck; Merck
Honoraria - BostonGene; Medscape; Prime Oncology
Consulting or Advisory Role - Curio Science; Exelixis; Gerson Lehrman Group; Guidepoint Pharmacy
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Laekna Health Care (Inst); Progenics (Inst); Xencor (Inst); Zenith Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Prime Oncology
 
Ari Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - George Clincal; West Clinic
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Jeffrey Miller
Stock and Other Ownership Interests - Fate Therapeutics; GT Biopharma
Consulting or Advisory Role - Fate Therapeutics; GT Biopharma; Vycellix
Research Funding - Fate Therapeutics; GT Biopharma
Patents, Royalties, Other Intellectual Property - Fate Therapeutics; GT Biopharma
Travel, Accommodations, Expenses - Fate Therapeutics; GT Biopharma
 
Emmanuel Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Frank Cichocki
Stock and Other Ownership Interests - Fate Therapeutics
Consulting or Advisory Role - Fate Therapeutics
Research Funding - Fate Therapeutics
 
Justin Hwang
Consulting or Advisory Role - Astrin Bio; Tempus
Research Funding - Astrin Biosciences